Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

Lorenzo Gianni, Bernard F. Cole, Ilaria Panzini, Raymond Snyder, Stig B. Holmberg, Michael Byrne, Diana Crivellari, Marco Colleoni, Stefan Aebi, Edda Simoncini, Olivia Pagani, Monica Castiglione-Gertsch, Karen N. Price, Aron Goldhirsch, Alan S. Coates, Alberto Ravaioli

Research output: Contribution to journalArticlepeer-review

Abstract

Goal of the work: Anemia is a common side effect of chemotherapy. Limited information exists about its incidence and risk factors. The objective of this study was to evaluate the incidence of anemia and risk factors for anemia occurrence in patients with early breast cancer who received adjuvant chemotherapy. Materials and methods: We evaluated risk factors for anemia in pre- and post/perimenopausal patients with lymph node-positive early breast cancer treated with adjuvant chemotherapy in two randomized trials. All patients received four cycles of doxorubicin and cyclophosphamide (AC) followed by three cycles of cyclophosphamide, methotrexate, fluorouracil (CMF). Anemia incidence was related to baseline risk factors. Multivariable analysis used logistic and Cox regression. Main results: Among the 2,215 available patients, anemia was recorded in 11% during adjuvant chemotherapy. Grade 2 and 3 anemia occurred in 4 and 1% of patients, respectively. Pretreatment hemoglobin and white blood cells (WBC) were significant predictors of anemia. Adjusted odds ratios (logistic regression) comparing highest versus lowest quartiles were 0.18 (P

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalSupportive Care in Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2008

Keywords

  • Adjuvant therapy
  • Adverse event
  • Anemia
  • Breast cancer
  • Chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Fingerprint

Dive into the research topics of 'Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group'. Together they form a unique fingerprint.

Cite this